Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs GeneDx Holdings Corp — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.82 (market cap $2.98B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: MicroSectors FANG and Innovation 3X Leveraged ETN is the larger of the two by market cap, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days and GeneDx Holdings Corp for 19 Days on average.
| FNGU | WGS | |
|---|---|---|
Market Cap | $2.98B | $2.02B |
Volume | 4,682,352 | 734,640 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $167.51 |
52-Week Low | $13.73 | $34.51 |
Typical Hold Time | 19 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3x leveraged ETN tracking major tech stocks, trades at $35.99, down 3.25% today. Technical indicators show a bullish trend with strong moving average support but neutral oscillators. The ETN faces significant volatility risks as highlighted by recent analysis showing it lost 87% during previous tech sector downturns. Support levels cluster around $33-35 with resistance at $37-39.
While leveraged exposure to AI leaders like Nvidia and Meta offers upside potential during tech rallies, the extreme volatility and historical drawdowns present substantial risk. Investors should weigh the potential for amplified returns against the documented vulnerability to sector corrections, requiring careful risk management in portfolio allocation.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
